* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Document
Therapeutic gene modulation wikipedia , lookup
Fetal origins hypothesis wikipedia , lookup
Deoxyribozyme wikipedia , lookup
Cell-free fetal DNA wikipedia , lookup
Comparative genomic hybridization wikipedia , lookup
Oncogenomics wikipedia , lookup
Extrachromosomal DNA wikipedia , lookup
Nutriepigenomics wikipedia , lookup
Medical genetics wikipedia , lookup
Molecular cloning wikipedia , lookup
Non-coding DNA wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Genome (book) wikipedia , lookup
Helitron (biology) wikipedia , lookup
Designer baby wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
History of genetic engineering wikipedia , lookup
Biochip Platforms for DNA Diagnostics 許文馨 游崇善 許家維 陳彥如 Introduction The DNA microarray is a form of biochip. Level of gene expression, polymorphism, and functional genomics. Biological recognition, microlithography(微影 技術). Biosensor. High>10,000 ,100<medium<10,000 , low<100 Microarrary=biochips, but biochips!=microarrary Biorecognition Substance: DNA, RNA, protein, along with subcellular organelles, cells and tissues. Biomimetic surfactant (界面活性劑)bilayers, physical entrapment, chemical coupling, localization within self-assembled polyelectrolyte(聚合電解質)layers. Unique and highly specific recognition Biodetection Methods Microelectromechanical system(MEMS) Optical devices Mass sensitive oscillating crystal devices Thermal detection Radio labelling Mass spectrometry Biodetection Methods Sensitivity Detection limit Response rate Throughput Microarrays Microarray technology “promises not only to dramatically speed up the experimental work of molecular biologists but also to make possible a whole new experimental approach in molecular biology”. 不只加快了實驗的速度,也提供了新的實驗方 法,是分子生化實驗的一大進展 Microarray Microarrays, principally DNA and proteins (although organelle, cellular and tissue microarrays are emerging), exploit an ordered, two-dimensional presentation of biorecognition entities, fluorescence or radio tagging of targets and scanning confocal or radio imaging of the recognition–target complex or product. Microarray,原則上是DNA和蛋白microarray , 發展成一個排序的,2維的生化辨識的entity, 以螢光或無線電標記目標,並且掃描共焦或無 線電影相來確認目標化合物或產物 Microarray To date, microarray technology, a largely semi-quantitative analytical technique, has been most valued in the basic research arena as a hypothesis-generating(假設 發展 )technique. Studies using microarrays have served to advance understanding of the disease process and, as the technology evolves, it will become a tool for clinical medicine, providing a rich source of information on disease susceptibility, diagnosis and prognosis. As a research tool, DNA microarrays have already been used in the study of breast cancer, leucaemia(白血病), heart, blood vessel and lung disease, cystic fibrosis(囊胞性纖維症 ), human immunodeficiency virus, cancer, astrocytomas(神經膠質瘤 ), toxicity(毒物) and single nucleotide polymorphisms(單一多型核甘 酸). They have been used more broadly as well to study Arabidopsis thaliana(阿拉伯芥 ), rat, yeast(酵母 ) and Escherichia coli(下痢性大腸桿菌 ) genomes(基因組), mouse models and others. The evolution of microarrays is to use the information gleaned(蒐集) from genomic microarrays in the development of pathway-specific, disease-state-specific or diagnostic/prognostic microarrays that employ smaller suites of genes in highly focused assessments. 已被廣泛用來研究 預防 診斷 預測 各種疾病 走向 反應路徑 以及 各種生物病菌的研究 Microarray Because of the semi-quantitative nature of today’s microarrays, the likely diagnostic arrays (biochips) of the future must be brought into a more quantitative format. Opportunities Diagnostics f or Biochip Opportunities for application of biochips are most attractive in the area of human health. The research and development (R&D) investments, marketing, sales and distribution costs, given today’s models for development of technology-based companies, do not support similar opportunities in the environment , industrial or bioprocess sectors. 生物晶片在人類健康領域上的機會與應用是目前最吸引 人的,反而在工業與生物加工區塊因為投資、成本與 市場環境的關係比較沒有發展。 The human health sector presents opportunities for drug development in the following areas: near-patient (bedside); doctor’s office; clinical laboratory; and molecular diagnostics laboratory (hospital). 而生物晶片在以下地區有機會開發: 病人身邊 醫生辦公室 臨床實驗室 醫院分子診斷實驗室 in the short term, diagnostic biochips are likely to have more impact in the area of drug development than in clinical molecular diagnostics. 短期內診斷型biochip 會被用在藥物預測開發 而不是臨床分子治療 Diagnostic biochips will feature prominently as the means for providing the critical molecular data for drug discovery. SNPs application 尋找致病基因 診斷及預測致病風險 藥物基因體學及新藥的發現 利用SNP與現有的基因診斷體系接軌,能加速檢驗醫學從 表型診斷轉向基因型診斷,並預防藥物副作用,提高療效 Impact and Challenges for Biochip Diagnostics Biochips Diagnostics major challenges Acceptable clinical detection limits Sensitivity and specificity Dynamic range Repeatability and reproducibility Response time Immunity from false positives and false negatives Biochip diagnostics of competitive advantage Higher throughput Smaller sample volume Such as in some tumour biopsies Integration of sample preparation This may reduce the overall cost per test performed On the same biochip platform Cost per test The impact of diagnostic biochips in molecular diagnostics must await the results of further research and targeted development. Millennium Predictive Medicine, Abbott Diagnostics, Bayer, Motorola Clinical Microsensor Systems, Nanogen, Inc. and ABTECH Scientific, are pursuing such diagnostic products actively. Abbott Diagnostics Bayer ABTECH Scientific Issues Related to Diagnostic Biochips 1.Software system 2.Appropriate complement of genes 3.Privacy rights 4.Powerful Databank 1.Software system The absence of a standard format for compating and transferring microaarrar data has produced proposals to create a standard ‘language’ to facilitate the sharing of sata among scientists. 2.Appropriate complement of genes An equitable and streamlined mechanism for licensing genes and allels would help to promote continued research,development and commercalization. 3.Privacy rights Are there adequate interventions or therapies for all conditions revealed by the screen? Are the privacy rights of patients protected adequately? Can adequate informed consent be obtained given the broad range of possible outcomes of the screen? 4.Powerful Databank Detailed health information(likely anomised or key-coded) in databank arepowerful and valuable tools to help understand and counteract disease process but raise questions of equitty of acess and parity of use in structuring enquiry for societal benefits. Epilogue A key driver for a biochip diagnostic must be a business case that is linked to technology acquisition or development . Even though biochip platforms have a long way to go before being revolutionise all aspects of preventing,diagnosing and treating disease that traditional drugbased medicine cannot hope to accomplish.